Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04570332
Title BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Highlight Therapeutics

mucosal melanoma

skin melanoma


BO-112 + Pembrolizumab

Age Groups: adult | senior
Covered Countries FRA | ESP

No variant requirements are available.